Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
15/04/2025 21:40
April 15 (Reuters) - ABVC Biopharma Inc ABVC.O: ABVC BIOPHARMA : CONCLUDED THAT FINANCIAL STATEMENTS FOR FY ENDED DEC 31, 2023 SHOULD NO LONGER BE RELIED UPON DUE TO ERRORS IN FINANCIAL STATEMENTS Source text: [ID:n0001213900-25-032135] Further company coverage: ABVC.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner